Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome.

Hristov AC, Vonderheid EC, Borowitz MJ.

Am J Clin Pathol. 2011 Dec;136(6):944-53. doi: 10.1309/AJCP09OTJOYAVZZK.

2.

The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.

Papadavid E, Economidou J, Psarra A, Kapsimali V, Mantzana V, Antoniou C, Limas K, Stratigos A, Stavrianeas N, Avgerinou G, Katsambas A.

Br J Dermatol. 2003 Apr;148(4):709-18.

PMID:
12752128
3.

Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.

Harmon CB, Witzig TE, Katzmann JA, Pittelkow MR.

J Am Acad Dermatol. 1996 Sep;35(3 Pt 1):404-10.

PMID:
8784277
4.

Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.

Wood GS, Hong SR, Sasaki DT, Abel EA, Hoppe RT, Warnke RA, Morhenn VB.

J Am Acad Dermatol. 1990 Apr;22(4):602-7.

PMID:
1690762
5.

The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.

Bernengo MG, Novelli M, Quaglino P, Lisa F, De Matteis A, Savoia P, Cappello N, Fierro MT.

Br J Dermatol. 2001 Jan;144(1):125-35.

PMID:
11167693
6.

Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome.

Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Steitz J, Roszkiewicz J, Bieber T, Tüting T.

Clin Exp Dermatol. 2005 Nov;30(6):702-6.

PMID:
16197392
7.

Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood.

Jones D, Dang NH, Duvic M, Washington LT, Huh YO.

Am J Clin Pathol. 2001 Jun;115(6):885-92.

8.

CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome.

Rappl G, Muche JM, Abken H, Sterry W, Tilgen W, Ugurel S, Reinhold U.

J Am Acad Dermatol. 2001 Mar;44(3):456-61.

PMID:
11209115
10.

Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.

Feng B, Jorgensen JL, Jones D, Chen SS, Hu Y, Medeiros LJ, Wang SA.

Mod Pathol. 2010 Feb;23(2):284-95. doi: 10.1038/modpathol.2009.175.

11.

Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.

Introcaso CE, Hess SD, Kamoun M, Ubriani R, Gelfand JM, Rook AH.

J Am Acad Dermatol. 2005 Sep;53(3):428-34.

PMID:
16112348
12.

Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome.

Lima M, Almeida J, dos Anjos Teixeira M, Queiros ML, Santos AH, Fonseca S, Balanzategui A, Justica B, Orfao A.

Haematologica. 2003 Aug;88(8):874-87.

13.

The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome.

Scala E, Abeni D, Pomponi D, Narducci MG, Lombardo GA, Mari A, Frontani M, Picchio MC, Pilla MA, Caprini E, Russo G.

Haematologica. 2010 Nov;95(11):1905-12. doi: 10.3324/haematol.2010.026260.

14.
15.

[Clinicomorphological characteristics of Sezary's disease and mycosis fungoides].

Vinogradova IuE, Giliazitdinova EA, Zamulaeva IA, Zybunova EE, Kaplanskaia IB, Kravchenko SK, Kremenetskaia AM, Lutsenko IN, Samoĭlova RS, Selivanova EN, Sidorova IuV, Shklovskiĭ-Kord NE.

Ter Arkh. 2005;77(10):61-5. Russian.

PMID:
16320688
16.

Genotypic, phenotypic and functional analysis of CD4+CD7+ and CD4+CD7- T lymphocyte subsets in Sézary syndrome.

Dummer R, Nestle FO, Niederer E, Ludwig E, Laine E, Grundmann H, Grob P, Burg G.

Arch Dermatol Res. 1999 Jun;291(6):307-11.

PMID:
10421055
17.

Diminished CD3 expression is useful for detecting and enumerating Sézary cells.

Edelman J, Meyerson HJ.

Am J Clin Pathol. 2000 Sep;114(3):467-77. Erratum in: Am J Clin Pathol 2001 Jan;115(1):161.

18.

Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.

Poenitz N, Simon-Ackermann J, Gratchev A, Qadoumi M, Klemke CD, Stadler R, Kremer A, Radenhausen M, Henke U, Assaf C, Utikal J, Goerdt S, Dippel E.

Dermatology. 2005;211(2):84-92.

PMID:
16088151
19.

Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT.

Arch Dermatol. 2003 Jul;139(7):857-66.

PMID:
12873880
20.

Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.

Vaughan J, Harrington AM, Hari PN, Kroft SH, Olteanu H.

Am J Clin Pathol. 2012 Mar;137(3):403-11. doi: 10.1309/AJCP7QHH5XASTJPL.

Items per page

Supplemental Content

Support Center